Centre for Anaesthesiological Research, Department of Anesthesiology, Zealand University Hospital, Køge, Denmark.
Department of Anesthesiology, Nykøbing Falster Hospital, Nykøbing Falster, Denmark.
Acta Anaesthesiol Scand. 2024 Aug;68(7):871-887. doi: 10.1111/aas.14425. Epub 2024 Apr 17.
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly recommended for perioperative opioid-sparing multimodal analgesic treatments. Concerns regarding the potential for serious adverse events (SAEs) associated with perioperative NSAID treatment are especially relevant following gastrointestinal surgery. We assessed the risks of SAEs with perioperative NSAID treatment in patients undergoing gastrointestinal surgery.
We conducted a systematic review of randomised clinical trials assessing the harmful effects of NSAIDs versus placebo, usual care or no intervention in patients undergoing gastrointestinal surgery. The primary outcome was an incidence of SAEs. We systematically searched for eligible trials in five major databases up to January 2024. We performed risk of bias assessments to account for systematic errors, trial sequential analysis (TSA) to account for the risks of random errors, performed meta-analyses using R and used the Grading of Recommendations Assessment, Development and Evaluation framework to describe the certainty of evidence.
We included 22 trials enrolling 1622 patients for our primary analyses. Most trials were at high risk of bias. Meta-analyses (risk ratio 0.78; 95% confidence interval [CI] 0.51-1.19; I = 4%; p = .24; very low certainty of evidence) and TSA indicated a lack of information on the effects of NSAIDs compared to placebo on the risks of SAEs. Post-hoc beta-binomial regression sensitivity analyses including trials with zero events showed a reduction in SAEs with NSAIDs versus placebo (odds ratio 0.73; CI 0.54-0.99; p = .042).
In adult patients undergoing gastrointestinal surgery, there was insufficient information to draw firm conclusions on the effects of NSAIDs on SAEs. The certainty of the evidence was very low.
非甾体抗炎药(NSAIDs)常用于围手术期阿片类药物节约多模式镇痛治疗。在胃肠道手术后,与围手术期 NSAID 治疗相关的严重不良事件(SAE)的潜在风险尤其相关。我们评估了胃肠道手术患者围手术期 NSAID 治疗的 SAE 风险。
我们对评估 NSAIDs 与安慰剂、常规护理或无干预在胃肠道手术患者中的有害影响的随机临床试验进行了系统回顾。主要结局是 SAE 的发生率。我们系统地在五个主要数据库中搜索了符合条件的试验,截至 2024 年 1 月。我们进行了风险偏倚评估以考虑系统误差,进行了试验序贯分析(TSA)以考虑随机误差的风险,使用 R 进行了荟萃分析,并使用推荐评估、制定和评估框架(GRADE)来描述证据的确定性。
我们纳入了 22 项试验,共有 1622 名患者进行了主要分析。大多数试验存在较高的偏倚风险。荟萃分析(风险比 0.78;95%置信区间 [CI] 0.51-1.19;I = 4%;p =.24;极低确定性证据)和 TSA 表明,与安慰剂相比,NSAIDs 对 SAE 风险的影响缺乏信息。包括零事件试验的贝塔二项式回归敏感性分析显示,与安慰剂相比,NSAIDs 可降低 SAE 的发生率(比值比 0.73;CI 0.54-0.99;p =.042)。
在接受胃肠道手术的成年患者中,尚无充分信息来确定 NSAIDs 对 SAE 的影响。证据的确定性非常低。